FineHeart took part in the 9th edition of the Innovaday investment forum, co-organized by Unitec and ADI Nouvelle-Aquitaine, on December 7 at the Hôtel de Région.
This forum, which aims to facilitate meetings between entrepreneurs, investors, financiers and innovation partners, is a real lever for the growth and development of innovation in the Nouvelle-Aquitaine region.
With over 500 participants, 77 national investors and 17 speakers, this event was an opportunity to highlight FineHeart through Arnaud Mascarell’s participation as speaker in the workshop on the theme of «Everything you need to know about the investor/entrepreneur relationship post fundraising». In addition to the workshops themes, the event also provided an opportunity for companies to exchange views with investors
In November 2023, FineHeart took part in the LiryConnect organized by the University of Bordeaux. This 2-day event brought together patients, researchers, healthcare professionals, healthtech startups, healthcare institutions, major healthcare industrial groups and development structures, to discuss the future of medicine, through the prism of data access, artificial intelligence, remote monitoring and entrepreneurship.
FineHeart took part in the 7th EACTS Mechanical Circulatory Support Summit in Copenhagen, Denmark. Aimed at specialists in the cardiovascular field, this event was a great opportunity for FineHeart to present the FlowMaker to an audience of specialists. Prof. Ivan Netuka, Chairman of the Department of Cardiovascular Surgery at Prague’s IKEM, who is responsible for the First in Human project, presented the device at a conference entitled “What’s in the pipeline – new medium and long-term devices”. The FineHeart team was also present with a stand in the company’s colors, and was able to interact and exchange views with congress participants on the latest advances in the sector.
FineHeart is very proud to be part of the Agence de l’innovation en santé 2023-2025 roadmap!
This selection alongside innovative HealthTech companies reinforces our commitment to playing a part in the future of medicine and our healthcare system.
FLOWMAKER has been authorised to start clinical trials. More than ever, it represents a huge hope for more than 200,000 patients who, every year, cannot benefit from current therapeutic solutions.
FineHeart was chosen to represent innovation in the healthtech sector in France’s Nouvelle-Aquitaine region, and was visited by Dr. Lise Alter, Director of the Agence de l’Innovation en Santé (AIS), as part of her “Tour of French regions”. This highly fruitful visit provided the opportunity to highlight the significant potential of the implantable medical device industry in France, and the need for support to be put in place to facilitate the transition from the research & development phase to industrialization.
Alain Rousset, President of France’s Nouvelle-Aquitaine Region has been a supporter of FineHeart from the start. He visited the company for an update on progress in the development of the FLOWMAKER®. The visit took place during “Europe Month”, which aims to showcase regional potential through innovation.
Mr. Rousset emphasized during the discussions that FineHeart’s industrial project is a good example of how to enhance France’s attractiveness and showcase its expertise in implantable medical devices.
FineHeart took part in the MedTech Strategist Innovation Summit in Dublin last April. A must-attend event for specialist investors looking for potential success stories in the medical device industry. This forum was another opportunity for FineHeart to make itself known to investors and industrial players interested in medical devices and cutting-edge technologies.
Our Chairman Jean-Luc Boulnois represented FineHeart at the LSI’23 Emerging Medtech Summit in California last March. Fineheart stood out as one of the few participants to present a truly breakthrough innovation.
FineHeart has completed a tour of the major international cardiology congresses, where we presented our abstract demonstrating the potential of sustained myocardial recovery. Prof. Finn Gustafsson, professor of severe heart failure and transplantation at the cardiology department of the Copenhagen Heart Centre, and Prof. Laurent Barandon, Director of the cardiology department of St-Augustin clinic in Bordeaux, presented the exceptional results of the preclinical trials of FLOWMAKER®, at the Heart Failure Congress in Prague and the ISHLT in Denver, respectively.
Organised by France Biotech, “Healthtech Trophies” promotes France’s HealthTech companies, whose dynamism and diversity of talent keep the sector alive and moving forward everyday. Selected in the MedTech category from among more than 100 candidates, FineHeart was one of the 4 finalists. This recognition once again highlighted FLOWMAKER’s ground-breaking innovation.